JP7750526B2 - 組み合わせ - Google Patents

組み合わせ

Info

Publication number
JP7750526B2
JP7750526B2 JP2022538232A JP2022538232A JP7750526B2 JP 7750526 B2 JP7750526 B2 JP 7750526B2 JP 2022538232 A JP2022538232 A JP 2022538232A JP 2022538232 A JP2022538232 A JP 2022538232A JP 7750526 B2 JP7750526 B2 JP 7750526B2
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
compound
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022538232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508332A5 (enExample
JP2023508332A (ja
Inventor
アブディ サマター，アフメド
リ，ジアリ
イザディ，フーマン
キンファ ファン，ピーター
ロバート ピンチマン，ジョセフ
クレイトン ボーレン，ブラント
デュアン バンカー，ケビン
ドネイト，フェルナンド
Original Assignee
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー filed Critical リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Publication of JP2023508332A publication Critical patent/JP2023508332A/ja
Publication of JP2023508332A5 publication Critical patent/JP2023508332A5/ja
Application granted granted Critical
Publication of JP7750526B2 publication Critical patent/JP7750526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022538232A 2019-12-20 2020-12-16 組み合わせ Active JP7750526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952032P 2019-12-20 2019-12-20
US62/952,032 2019-12-20
PCT/US2020/065410 WO2021127045A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (3)

Publication Number Publication Date
JP2023508332A JP2023508332A (ja) 2023-03-02
JP2023508332A5 JP2023508332A5 (enExample) 2023-12-25
JP7750526B2 true JP7750526B2 (ja) 2025-10-07

Family

ID=76478077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538232A Active JP7750526B2 (ja) 2019-12-20 2020-12-16 組み合わせ

Country Status (12)

Country Link
US (1) US20230054854A1 (enExample)
EP (1) EP4069242A4 (enExample)
JP (1) JP7750526B2 (enExample)
KR (1) KR20220119420A (enExample)
CN (2) CN121102230A (enExample)
AU (1) AU2020404996A1 (enExample)
BR (1) BR112022012283A2 (enExample)
CA (1) CA3165474A1 (enExample)
IL (1) IL294094A (enExample)
MX (1) MX2022007623A (enExample)
TW (1) TWI875898B (enExample)
WO (1) WO2021127045A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566612A3 (en) 2018-03-09 2025-08-20 Recurium IP Holdings, LLC Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
WO2022011391A1 (en) 2020-07-09 2022-01-13 Recurium Ip Holdings, Llc Salts and forms of a wee1 inhibitor
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023147297A2 (en) * 2022-01-25 2023-08-03 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173082A1 (en) 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102124715B1 (ko) * 2015-11-03 2020-06-18 제넨테크, 인크. 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
KR20200108301A (ko) * 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
WO2019165204A1 (en) * 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
US12220415B2 (en) * 2018-02-28 2025-02-11 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173082A1 (en) 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRANDWEIN MJ., et al.，BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML，Blood，2019年，Vol. 134 (Supplement_1) 2646，pp. 1-2

Also Published As

Publication number Publication date
TW202135819A (zh) 2021-10-01
CN115135325A (zh) 2022-09-30
BR112022012283A2 (pt) 2022-08-30
WO2021127045A1 (en) 2021-06-24
CN115135325B (zh) 2026-04-03
AU2020404996A1 (en) 2022-07-14
EP4069242A4 (en) 2024-01-10
CA3165474A1 (en) 2021-06-24
CN121102230A (zh) 2025-12-12
NZ790037A (en) 2025-08-29
US20230054854A1 (en) 2023-02-23
JP2023508332A (ja) 2023-03-02
EP4069242A1 (en) 2022-10-12
MX2022007623A (es) 2022-09-23
IL294094A (en) 2022-08-01
KR20220119420A (ko) 2022-08-29
TWI875898B (zh) 2025-03-11

Similar Documents

Publication Publication Date Title
JP7750526B2 (ja) 組み合わせ
JP7631348B2 (ja) 組み合わせ
JP2023508325A (ja) 組み合わせ
JP7794448B2 (ja) 組み合わせ
JP2023507797A (ja) 組み合わせ
KR20220119427A (ko) 조합
JP2023507799A (ja) 組み合わせ
RU2840819C1 (ru) Комбинации
JP2023525022A (ja) 組み合わせ
JP2023545498A (ja) Ｂｃｌ－２阻害剤と化学療法剤との組み合わせ
JP2023508324A (ja) 組み合わせ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250917

R150 Certificate of patent or registration of utility model

Ref document number: 7750526

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150